Swiss National Bank Inovio Pharmaceuticals, Inc. Transaction History

Swiss National Bank

$143 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$0.79 - $1.91 $50,323 - $121,667	-63,700 Reduced 10.58%	538,500 $441,000
Q4 2022 Feb 08, 2023	BUY	$1.41 - $2.5 $83,331 - $147,750	59,100 Added 10.88%	602,200 $939,000
Q3 2022 Nov 09, 2022	BUY	$1.66 - $2.79 $75,696 - $127,224	45,600 Added 9.17%	543,100 $937,000
Q1 2022 May 09, 2022	BUY	$2.97 - $5.2 $103,059 - $180,440	34,700 Added 7.5%	497,500 $1.79 Million
Q4 2021 Feb 08, 2022	BUY	$4.99 - $7.46 $12,974 - $19,396	2,600 Added 0.56%	462,800 $2.31 Million
Q3 2021 Nov 08, 2021	BUY	$7.16 - $9.69 $32,220 - $43,605	4,500 Added 0.99%	460,200 $3.3 Million
Q2 2021 Aug 06, 2021	SELL	$6.23 - $10.03 $104,041 - $167,501	-16,700 Reduced 3.54%	455,700 $4.22 Million
Q1 2021 May 07, 2021	BUY	$8.81 - $16.96 $825,497 - $1.59 Million	93,700 Added 24.74%	472,400 $4.38 Million
Q4 2020 Feb 05, 2021	BUY	$8.5 - $12.85 $173,400 - $262,140	20,400 Added 5.69%	378,700 $3.35 Million
Q3 2020 Nov 09, 2020	BUY	$9.57 - $27.05 $311,982 - $881,830	32,600 Added 10.01%	358,300 $4.16 Million
Q2 2020 Aug 05, 2020	BUY	$7.14 - $31.69 $2.33 Million - $10.3 Million	325,700 New	325,700 $8.78 Million
Q4 2019 Feb 06, 2020	SELL	$1.97 - $3.72 $344,356 - $650,256	-174,800 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$2.05 - $3.02 $20,090 - $29,596	9,800 Added 5.94%	174,800 $358,000
Q1 2019 May 10, 2019	BUY	$3.34 - $5.1 $28,724 - $43,860	8,600 Added 5.5%	165,000 $615,000
Q1 2018 May 04, 2018	BUY	$4.05 - $5.69 $71,685 - $100,713	17,700 Added 12.76%	156,400 $737,000
Q3 2017 Nov 03, 2017	BUY	$5.36 - $6.37 $743,432 - $883,519	138,700	138,700 $879,000

Others Institutions Holding INO

# of Institutions

Shares Held

281K

Call Options Held

Put Options Held

View Full List

About INOVIO PHARMACEUTICALS, INC.

Ticker INO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 249,400,000
Market Cap $1.41B
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA se...

More about INO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account